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Parkinson’s disease (PD) is considered a multifactorial dis-
order, which is neuropathologically characterized by age-
dependent neurodegeneration of dopaminergic neurons in
the midbrain. Diﬀerent neurotoxins including synthetic
compounds, heavy metals, and dopamine itself have been
proposed to be environmental risk factors of PD. Recent
genome-wide genetic and mutational studies provide infor-
mation on various genetic risk factors while microglial acti-
vation in the aﬀected regions has emerged to be involved
in the disease development as a local microenvironmental
factor. A wide variety of animal models of PD substantially
contribute to the understanding of these issues and the
development of therapeutic approaches as an alternative to
humans although none of them fully recaptures the symp-
toms and pathology of PD. This special issue is composed of
9 excellent reviews and 3 distinguished original articles that
summarize the most recent progresses and ideas obtained
from animal models in the pertinent ﬁeld, while reporting
the putative molecular mechanisms of neurodegeneration,
therapeutic challenges and limitations using PD models, and
generation of new versions of PD models.
The ﬁrst review paper brieﬂy outlines animal models of
PD, covering toxin-induced and genetic models of vertebrate
and invertebrate animals, in which characteristic features of
each model are discussed.
Mishandling of monoamines including dopamine has
been hypothesized to damage neurons. The second review
paperdescribesmicewithimpairedfunctionsofthevesicular
monoamine transporterVMAT2,inwhichprogressivelossof
catecholamine-secreting neurons is observed. Such models
may be potentially useful for the development of new
therapeutic strategies, which would complement current
dopamine replacement.
Neuropathological analysis of the postmortem PD brain
tissues suggests that an adverse interaction with surrounding
glia and other nonneuronal cells may be one of critical
steps in neurodegeneration. The third review highlights
endotoxin-induced inﬂammation models, in which activa-
tion of microglia and lymphocyte by a bacterial lipopolysac-
charide deteriorates a healthy relationship with neurons.
Mutations in the leucine-rich repeat kinase 2 (LRRK2)
gene have been identiﬁed to cause autosomal-dominant
late-onset PD and are also implicated in sporadic PD. The
neuropathological features of PD brain tissues with the
LRRK2 mutations are characterized by typical Lewy body
pathologyinthebrainstem. Theforth paperreviewsavariety
of LRRK2-related models.
Mutations and increased expression in the α-synuclein
gene cause the development of early-onset familial PD. The
formation of α-synuclein ﬁbrils and aggregates, a main com-
ponentofLewy bodiesand Lewy neurites, isconsidereda key
process in the pathogenesis of PD and other synucleino-
phathies. Other genetic determinants include the genes for
Mendelian forms of PD and susceptible genes. The following
two papers focus on the potential of Drosophila genetic
models to examine α-synuclein and other responsible genes.2 Parkinson’s Disease
Deep brain stimulation (DBS) by electrical pulses could
be one of useful therapeutic avenues for PD. However, DBS’s
technique requires advancement and poor understanding of
the mechanisms involved hinder application in clinical prac-
tice. The seventh review paper discusses the optimization of
a rat PD model for DBS.
Hydrogen has turned out to reduce oxidative damage.
The eighth paper introduces the neuroprotective eﬀects of
hydrogen on experimental animal models for PD and pos-
sible application in treatment and prevention of PD.
Thelastreviewexplainsthelimitationsofanimal models,
showing diﬀerences between humans and animals, and dif-
ﬁculties in interpretation of obtained results with animal
models.
The ﬁrst research paper investigates selective degenera-
tion of dopaminergic neurons in the substantia nigra and
associated motor dysfunction induced by inhalation of
mixed manganese compounds on mice. This model could
be instrumental for evaluating some aspects of a progressive
loss of dopaminergic neurons. The second research paper
examines the possible eﬀects of testosterone on PD using a
mouse model induced by 1-methy-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP) administration. The study suggests that
loss of testosterone induces remodeling in the morphology
of medium spiny neurons where dopaminergic neurons of
the substantia nigra project although no interaction between
testosterone and loss of dopaminergic neurons by MPTP
administration is observed. The third research paper of
this special issue addresses improvement of potential gene
therapy to compensate for impaired complex I activity of
the mitochondria using the yeast single-subunit NADH-
ubiquinoneoxidoreductase, NDI1.NDI1 is functionally able
to replace complex I, activity of which is thought to be
compromised in most of PD cases.
A decreased sense of smell is one of early signs of PD.
Althoughdegenerationoftyrosine hydroxylase-positive neu-
rons in the olfactory bulbs is observed, the pathogenic
mechanism underlying olfactory deﬁcits is not well under-
stood. The forth research paper addresses this issue using a
rat model bearing the pathogenic α-synuclein.
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